Merck (MRK) Cash & Current Investments (2009 - 2026)

Merck has disclosed Cash & Current Investments across 18 years of filings, most recently posting $5.7 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 38.21% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $5.7 billion (down 38.21% YoY), while the FY2025 annual figure was $14.6 billion, up 6.4% from the prior year.
• Cash & Current Investments eased to $5.7 billion in Q1 2026, from $14.6 billion in the prior quarter.
• Over the last five years, Cash & Current Investments for MRK reached as high as $18.2 billion in Q3 2025 and fell as low as $5.6 billion in Q1 2024.
• The 5-year median for Cash & Current Investments is $10.1 billion (2022), against an average of $10.5 billion.
• Annual changes were most pronounced in 2023 — Cash & Current Investments tumbled 46.23% — and 2024, when it jumped 92.99%.
• A 5-year view of Cash & Current Investments shows it stood at $13.2 billion in 2022, then plunged by 46.23% to $7.1 billion in 2023, then soared by 92.99% to $13.7 billion in 2024, then climbed by 6.4% to $14.6 billion in 2025, then plunged by 60.85% to $5.7 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $5.7 billion, $14.6 billion, and $18.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.